Literature DB >> 3058486

Pharmacokinetics of intravenous captopril in healthy men.

W A Creasey1, R A Morrison, S M Singhvi, D A Willard.   

Abstract

The pharmacokinetic characteristics of intravenously-administered captopril were investigated in 7 healthy men 20 to 33 years old. Capropril, labeled with 14C, was given by injection over a 1 min period at mean doses of 2.78 mg (13.8 microCi), 5.67 mg (28.2 microCi) and 11.4 mg (56.8 microCi). Concentrations of unchanged captopril, captopril disulfide, and other metabolites (collectively) were determined in body fluids. Pharmacokinetic parameters were calculated for unchanged captopril, and it was shown that the disposition of intravenously-administered drug was linear with respect to dose over the dosage range studied.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3058486     DOI： 10.1007/bf00561366

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  9 in total

1.  Hypertension and the renin-angiotensin system following open-heart surgery.

Authors:  K M Taylor; I J Morton; J J Brown; W H Bain; P K Caves
Journal:  J Thorac Cardiovasc Surg       Date:  1977-12       Impact factor: 5.209

2.  Intravenous captopril for cardiac failure.

Authors:  O Boyd; J E Pohl
Journal:  Lancet       Date:  1986-05-03       Impact factor: 79.321

3.  Captopril: five years on.

Authors:  G P Hodsman; J I Robertson
Journal:  Br Med J (Clin Res Ed)       Date:  1983-09-24

4.  Effect of food on the bioavailability of captopril in healthy subjects.

Authors:  S M Singhvi; D N McKinstry; J M Shaw; D A Willard; B H Migdalof
Journal:  J Clin Pharmacol       Date:  1982 Feb-Mar       Impact factor: 3.126

5.  Disposition of captopril in normal subjects.

Authors:  K J Kripalani; D N McKinstry; S M Singhvi; D A Willard; R A Vukovich; B H Migdalof
Journal:  Clin Pharmacol Ther       Date:  1980-05       Impact factor: 6.875

6.  A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation.

Authors:  K C Yeh; K C Kwan
Journal:  J Pharmacokinet Biopharm       Date:  1978-02

Review 7.  Captopril: pharmacology, metabolism and disposition.

Authors:  B H Migdalof; M J Antonaccio; D N McKinstry; S M Singhvi; S J Lan; P Egli; K J Kripalani
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

8.  Long-term antihypertensive therapy with captopril.

Authors:  J T Groel; S S Tadros; G R Dreslinski; A C Jenkins
Journal:  Hypertension       Date:  1983 Sep-Oct       Impact factor: 10.190

9.  Captopril kinetics.

Authors:  K L Duchin; S M Singhvi; D A Willard; B H Migdalof; D N McKinstry
Journal:  Clin Pharmacol Ther       Date:  1982-04       Impact factor: 6.875
  9 in total
  3 in total

1.  Studies with low dose intravenous diacid ACE inhibitor (perindoprilat) infusions in normotensive male volunteers.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1992-08       Impact factor: 4.335

Review 2.  Antihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approaches.

Authors:  Aikaterini Zisaki; Ljubisa Miskovic; Vassily Hatzimanikatis
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

3.  Development and evaluation of physiologically based pharmacokinetic drug-disease models for predicting captopril pharmacokinetics in chronic diseases.

Authors:  Muhammad F Rasool; Shazia Ali; Sundus Khalid; Ramsha Khalid; Abdul Majeed; Imran Imran; Hamid Saeed; Muhammad Usman; Mohsin Ali; Amer S Alali; Abdullah F AlAsmari; Nemat Ali; Ali Mohammed Asiri; Fawaz Alasmari; Faleh Alqahtani
Journal:  Sci Rep       Date:  2021-04-21       Impact factor: 4.379
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.